|
| Press Releases |
|
 |
|
| Monday, September 5, 2022 |
|
|
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC |
| Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs. more info >> |
|
| Friday, September 2, 2022 |
|
|
亞太地區吸引了50%的全球臨床試驗 根據新的GlobalData報告 |
| 亞太地區領先的生物技術臨床研究機構 Novotech 在一份題為“亞太地區臨床試驗的演變”的報告中發布了新的市場數據。該報告由 GlobalData 編寫，並確認“亞太地區 (APAC) 地區是 2017 年至 2021 年全球臨床試驗格局的最大貢獻者，佔分析期間進行的試驗的 50% 以上。” more info >> |
|
|
亚太地区吸引了50%的全球临床试验 根据新的GlobalData报告 |
| more info >> |
|
|
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report |
| Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled "Evolution of Clinical Trials in the Asia Pacific Region". The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period." more info >> |
|
| Tuesday, July 26, 2022 |
|
|
노보텍의 유연 근무 정책, 최고 유연 근무 프로그램의 ‘2022년 우수상’ 최종 후보로 선정 |
| 미국으로 서비스를 확장한, 아시아 태평양 지역 바이오테크 전문 임상 시험수탁기관(CRO)인 노보텍(Novotech)은 유연 근무에 대한 자사의 혁신적인 접근 방식을 인정받았다. more info >> |
|
| Monday, July 25, 2022 |
|
|
Novotech 的靈活工作政策入圍最佳工作場所靈活性計劃“2022 年卓越獎” |
| Novotech 是亞太地區領先的生物技術臨床研究機構，近期入駐美國，因其創新的工作場所靈活性方法而獲得認可。 more info >> |
|
|
Novotech 的灵活工作政策入围最佳工作场所灵活性计划“2022 年卓越奖” |
| Novotech 是亚太地区领先的生物技术临床研究机构，近期入驻美国，因其创新的工作场所灵活性方法而获得认可。 more info >> |
|
|
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022" |
| Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility. more info >> |
|
| Tuesday, July 19, 2022 |
|
|
노보텍과 엔드포인트, “중국의 세포 및 유전자 치료의 진화: 범용성 CAR-T 사례”에 관해 발표 |
| 미국으로 서비스를 확장한, 아시아 태평양 지역 바이오테크 전문 임상 시험수탁기관(CRO)인 노보텍(Novotech)은 ‘현 상황과 미래의 기회’란 주제로 중국의 CAR-T 치료법에 관한 엔드포인트 웨비나를 진행할 예정이다. more info >> |
|
|
Novotech和Endpoints展示“中國細胞和基因治療的演變：通用CAR-T的案例” |
| Novotech 是亞太地區領先的生物技術專家 CRO，在美國提供擴展服務，很高興在中國舉辦一場關於 CAR-T 治療的 Endpoints 網絡研討會——當前形勢和未來機遇。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 13:10 HKT/SGT
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 13:00: JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 12:46: JST
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 12:00 HKT/SGT
|
|
|
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 11:46 HKT/SGT
|
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million
Jun 12, 2025 21:07 HKT/SGT
|
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元
Jun 12, 2025 20:58 HKT/SGT
|
|
|
健倍苗苗二零二五财年全年业绩表现亮眼 纯利飙升51.2%至1.97亿港元
Jun 12, 2025 20:48 HKT/SGT
|
|
|
品質基石的守護者：檢測檢驗行業賦能高質量發展
Jun 12, 2025 18:28 HKT/SGT
|
|
|
质量基石的守护者：检测检验行业赋能高质量发展
Jun 12, 2025 18:19 HKT/SGT
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 17:38: JST
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 16:38 HKT/SGT
|
|
|
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
Jun 12, 2025 16:31 HKT/SGT
|
|
|
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Jun 12, 2025 16:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
